File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparative performance of two commercial sample-to-result systems for hepatitis C virus quantitation and genotyping

TitleComparative performance of two commercial sample-to-result systems for hepatitis C virus quantitation and genotyping
Authors
KeywordsHepatitis C virus
real-time RT-PCR
genotyping
diagnostic test evaluation
genotype 6
Issue Date2020
PublisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/iero20#.VgGYxUaFOnI
Citation
Expert Review of Molecular Diagnostics, 2020, v. 20 n. 12, p. 1253-1258 How to Cite?
AbstractObjectives: Accurate assays for hepatitis C virus (HCV) quantitation and genotyping are important for the management of HCV infection. In this study, we evaluated the performance of cobas HCV and cobas HCV GT assays (Roche) for HCV quantitation and genotyping on the cobas 4800 System. Methods: We compared the performance of the cobas HCV assays with another commercial system (Abbott m2000) using a panel of well-characterized patient samples and proficiency testing samples. Results: The limit-of-detection of the cobas HCV assay in our center was higher (15 IU/mL) than the manufacturer claim (9.2 IU/mL). The assay showed high analytical specificity, accuracy, precision, and linearity. Performance was congruent with the RealTime HCV assay (Abbott). For genotyping, the cobas HCV GT assay only showed moderate agreement with the RealTime HCV Genotype II assay (kappa = 0.550). The cobas assay outperformed the RealTime assay for typing HCV genotypes 1b and 6 (p = 0.033). Conclusion: Our results confirm that the cobas 4800 System is a reliable platform for HCV quantitation and genotyping. The cobas HCV GT assay is a good choice for genotype 1b/6 endemic areas in east Asia, clearly outperforming the RealTime HCV Genotype II assay.
Persistent Identifierhttp://hdl.handle.net/10722/304998
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 0.823
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYip, CY-
dc.contributor.authorSridhar, S-
dc.contributor.authorLau, JHN-
dc.contributor.authorCheng, AKW-
dc.contributor.authorLeung, KH-
dc.contributor.authorChen, JHK-
dc.contributor.authorChan, KH-
dc.contributor.authorCheng, VCC-
dc.contributor.authorYuen, KY-
dc.date.accessioned2021-10-05T02:38:16Z-
dc.date.available2021-10-05T02:38:16Z-
dc.date.issued2020-
dc.identifier.citationExpert Review of Molecular Diagnostics, 2020, v. 20 n. 12, p. 1253-1258-
dc.identifier.issn1473-7159-
dc.identifier.urihttp://hdl.handle.net/10722/304998-
dc.description.abstractObjectives: Accurate assays for hepatitis C virus (HCV) quantitation and genotyping are important for the management of HCV infection. In this study, we evaluated the performance of cobas HCV and cobas HCV GT assays (Roche) for HCV quantitation and genotyping on the cobas 4800 System. Methods: We compared the performance of the cobas HCV assays with another commercial system (Abbott m2000) using a panel of well-characterized patient samples and proficiency testing samples. Results: The limit-of-detection of the cobas HCV assay in our center was higher (15 IU/mL) than the manufacturer claim (9.2 IU/mL). The assay showed high analytical specificity, accuracy, precision, and linearity. Performance was congruent with the RealTime HCV assay (Abbott). For genotyping, the cobas HCV GT assay only showed moderate agreement with the RealTime HCV Genotype II assay (kappa = 0.550). The cobas assay outperformed the RealTime assay for typing HCV genotypes 1b and 6 (p = 0.033). Conclusion: Our results confirm that the cobas 4800 System is a reliable platform for HCV quantitation and genotyping. The cobas HCV GT assay is a good choice for genotype 1b/6 endemic areas in east Asia, clearly outperforming the RealTime HCV Genotype II assay.-
dc.languageeng-
dc.publisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/iero20#.VgGYxUaFOnI-
dc.relation.ispartofExpert Review of Molecular Diagnostics-
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectHepatitis C virus-
dc.subjectreal-time RT-PCR-
dc.subjectgenotyping-
dc.subjectdiagnostic test evaluation-
dc.subjectgenotype 6-
dc.titleComparative performance of two commercial sample-to-result systems for hepatitis C virus quantitation and genotyping-
dc.typeArticle-
dc.identifier.emailYip, CY: yipcyril@hku.hk-
dc.identifier.emailSridhar, S: sid8998@hku.hk-
dc.identifier.emailLeung, KH: khl17@hku.hk-
dc.identifier.emailChen, JHK: jonchk@hku.hk-
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityYip, CY=rp01721-
dc.identifier.authoritySridhar, S=rp02249-
dc.identifier.authorityChan, KH=rp01921-
dc.identifier.authorityYuen, KY=rp00366-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/14737159.2020.1820327-
dc.identifier.pmid32893699-
dc.identifier.scopuseid_2-s2.0-85091393088-
dc.identifier.hkuros325983-
dc.identifier.volume20-
dc.identifier.issue12-
dc.identifier.spage1253-
dc.identifier.epage1258-
dc.identifier.isiWOS:000572223500001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats